Kind of nice to see it pulling back from its highs. At this stage, hopefully folks took the gains it gave with a disclaimer that I did sell out way too soon as I didn't see the run getting as crazy as it did.
But that said, liking the pullback. Chart is suggesting more downside is 'possible'. Given that they won't complete the study until in 2024? IF this market continues to 'sour', expecting it to get 'cheaper'..
Disclaimer: like it, but own none at the moment. Just checking into see if anyone had anything to say..
Why NSPR went up so much while its OS had just been diluted by nearly Three-Baggers? Who currently hold those Newly-Diluted 12,887,999 shares?
Note, the Cash Value is only mere $0.54344 a share but its price was up to $3.77 a share most recently! Why this stock's price could be as much as nearly SEVEN Times of its actual Cash Value?
Anyway its Book Value is only $2.204 a share!
Will NSPR crash back to its 52-week-low $0.8064 again in the coming weeks/months?
Well, now the CH7 Bankruptcy seems impossible in the short term for NSPR based on its improved new balance sheet from the latest financial report.
The OS of NSPR had been diluted to 21,244,393 shares on 09/09/2023 from 8,356,394 shares on 05/14/2023! Why such huge dilutions in such short period?
NSPR had already bounced up significantly --- Up 4.68-Bagger or 367.51% to $3.77 so far from its Bottom $0.8064!
InspireMD Inc NASDAQ: NSPR
Health Care : Health Care
Equipment & Supplies | Small Cap Value | Based in IsraelCompany profile
InspireMD, Inc. is a medical device company. The Company is focusing on the development and
commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary
disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in
stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet
and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Had bought a few thousand shares @ $1.35 and lower range.. Sold them on this pop at around $1.90. Long ways to the 1st qtr 2024 when this trial ends..
Hopefully the share price retries the $1.50 or below level.. Would like to buy another round..
Anything is possible, but my 1st target price range is $3 - 4, maybe $5.
1. established competition, going to have to demo they are 'worth' being the one 'desired'
2. non-US based company. Will the market embrace them, give them a favorable share price
And of course, is WHEN is it 'possible' and that won't be until the end of the Ph 3 monitoring period is complete in my estimation. Which of course is into early 2024
But in the act of disclosure, just starting to accumulate shares figuring a 2-3x return from this price range would be pretty darn good.
Note, NSPR did surge 5.1035-Bagger from previous Bottom $4.35 on 09/24/2020 to its recent high $22.2 on 02/11/2021 when all least expected! Which means it can Easily bounce to $4.12 with the Same performance...
What I THINK I know:
-1st qtr 2023, expected to complete enrollment
-1st qtr 2024 timeframe: end of the 12 month follow up monitoring
-2nd qtr 2024 (maybe??): PH 3 trial results
-9 months or so later: up for an FDA decision, so likely at the earliest, end of 2024 for the approval decision (??) 2+ YEARS from now
-still working to expand sales in overseas markets, but realistically, needs the US market approval
That said, then there is the bigger challenge to come and that is, breaking in/capturing market share from some established big market players who
i doubt will easily see their revenue stream 'interrupted' by an upstart. So the question will end up being one of, is this that much better than whats on the market NOW. Will it be that much better that a shift will occur simply because of the advantages/benefits of the design or will the market say, what we have is 'good enough' and the design is a tough sell, slow to gain market share if any.
As a disclaimer: I finally bought a few thousand shares at $1.14. And I plan to add more simply for the PR events to come (ie, completed enrollment, any planned data releases, NDA filing, et al cause they do get the markets attention. So while I expect there to be opportunities to see gains develop from this price level, I am not sold that this WILL get a good toe hold in the US market at this point in time. But given the low share count, I do see a move to $4-5/sh from this price level as achievable. Which is why I wanted 'some shares' before I get surprised by a jump for something I didn't see coming.
NSPR might take off anytime from now on and surge back to its recent high $22.2 again very soon when we least expect it because this NASDAQ Bio-Tech Hidden Gem only has mere 8.3M shares of Super Tiny OS count...
This Hidden Gem should run the Same 5.2-Bagger Quick rally first to hit $7.228 like its OTC peer (PBHG: from previous Bottom 0.0005 to 0.0026) did most recently!
Note, NSPR will surge to a New 52-week-high $7.094 from current 52-week-low $1.39 based on the Same past bouncing performance --- from previous Bottom $4.35 (on 09/24/2020) to its recent high $22.2 (on 02/11/2021)!
Can NSPR hit $22.2 again in the coming months?
want to get shares, but having to wait for another one to get over a hurdle.
So not in a hurry to see this one 'take off'.. till at least into the 3rd, preferrably the 4th qtr
No. I called in the company and the management said that NSPR has ZERO Debt and Very Positive Cash Value & Book Value! Therefore there is no way to file the bankruptcy based on current Strong financial balance sheet!
With only 8.3M shares of the Super Tiny OS count how could NSPR crash to such ridiculous low price levels?
The Huge Diluting Pos Scam crashed to $3.11 last Friday! Sell ASAP because NSPR will test the Bottom $3.11 again in the coming days/weeks...
When can you see its most recent high $5.06 again? In the January of 2022?
How could NSPR surge to eye-popping high $22.2 back to this February? What drove this Huge Quick rally?
Can NSPR surge to $17.09 before the end of 2022 in order to bounce the Same 5.4951-Bagger as before --- from previous Bottom $4.04 to $22.2?
This Huge Diluting Pos Scam just crashed to Another New 52-week-low $3.395 today! Sell ASAP...
How could it surge to eye-popping high $22.2 back to this February? What drove this Huge Quick rally?
Can NSPR hit $18.66 again to bounce the Same percentage as before --- from previous Bottom $4.04 to $22.2?
Wait You Should Buy More.lol
some conference today, looks like 'someone' likes what they heard, up 64 cents today.
Damn.. was hoping it would drop to $4 with around a year just to enroll enough folks for the 12 month follow up period that comes next.
disclaimer: have traded the shares a few times, but own none at the moment as I was monitoring the slow slide.. (till it wasn't)